Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 3722 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

Daiichi Sankyo files for WelChol label change

WelChol is currently indicated for the reduction of LDL-C either alone or in combination with commonly prescribed statins such as Lipitor, Zocor, Pravachol and Mevacor. A study recently

Protox begins early stage study

Protox believes the drug's unique mechanism of action could change the way patients with enlarged prostate are treated. It said that the drug, PRX302, could be used to

Seattle, Genentech extend antibody agreement

<p>Genentech will exercise exclusive licenses to specific targets and use Seattle Genetics&#0039; antibody-drug conjugate (ADC) technology. ADCs utilize the targeting ability of monoclonal antibodies to deliver potent, cell-killing

Pharmacopeia earns $1 million payment

Schering-Plough is solely responsible for further development and commercialization of this inflammatory disease candidate. However, Pharmacopeia is eligible to receive additional milestone payments if the program advances further

Medicines Company drug stabilises blood pressure

The program compared Cleviprex to current intravenous antihypertensive agents: nitroglycerin, sodium nitroprusside or nicardipine. Cleviprex met all primary endpoints in the trial. “Given the trial successfully met all

CuraGen, TopoTarget begin myeloma trial

The companies have initiated this trial based on preliminary safety results from ongoing phase Ib trials evaluating belinostat in combination with Velcade. The phase II trial will assess

NicOx receives milestone payment from Pfizer

The glaucoma drug, PF-03187207, is the lead development compound generated under the August 2004 collaboration agreement between Pfizer and NicOx, which is focused on the development of nitric